News
Public · Published
ABBV: Immunology and neuroscience growth lifted revenue 10.3%; FY26 EPS guidance rose
Q3 revenue rose 10.3%, with adjusted diluted EPS of $3.82 and strong immunology and neuroscience growth. FY26 adjusted EPS guidance increased to $13.95–$13.99. The Apogee acquisition was completed and the dividend rose 5.2%.
Published:
Updated:
What happened
Q3 revenue rose 10.3%, with adjusted diluted EPS of $3.82 and strong immunology and neuroscience growth. FY26 adjusted EPS guidance increased to $13.95–$13.99. The Apogee acquisition was completed and the dividend rose 5.2%.
Confirmed
Global impact / market context
Higher revenue and raised FY26 adjusted EPS guidance suggest the company expects more earnings per share ahead, which can support the dividend and fund integration of the Apogee acquisition. Strong immunology and neuroscience growth shows which parts of the business are driving results.
Analyst inference
Investors comparing AbbVie with other drugmakers may focus on whether immunology and neuroscience growth can offset weaker areas, and on how the Apogee acquisition and higher dividend affect cash available. Raised guidance signals management expects profit per share to improve.
Analyst inference
What to watch
- FY26 adjusted EPS guidance is now $13.95–$13.99, so results within that range would show whether management's profit per share forecast holds. Confirmed
- The Apogee acquisition was completed; watch integration progress and any updates on how it contributes to revenue and costs. Proposed
- Watch whether immunology and neuroscience growth continues, since those areas drove Q3 revenue and support the raised guidance and higher dividend. Analyst inference
Evidence
- Original source link unavailable